Prophylactic Human Papillomavirus Vaccines - Canada Drug Forecast and Market Analysis to 2022

Researchmoz presents this most up-to-date research on"PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Canada Drug Forecast and Market Analysis to 2022". The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Market.

Browse Detail Report with TOC @ http://www.researchmoz.us/pharmapoint-prophylactic-human-papillomavirus-vaccines-canada-drug-forecast-and-market-analysis-to-2022-report.html

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries.



The current HPV vaccines market is dominated by one major player, Mercks Gardasil, with GlaxoSmithKlines (GSKs) HPV vaccine Cervarix providing the only competition. The introduction of Mercks nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

Browse Pharmaceutical Related Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

The anticipated addition of boys to routine HPV vaccine recommendations by different Canadian provinces is expected to serve as a significant driver to growth within the HPV vaccines market in Canada over the forecast period. In addition, from primary research insight, GlobalData projects Mercks nine-valent vaccine V503 to be widely adopted in the country. This will also significantly enhance the size of the HPV vaccines sector in Canada.

Scope
Overview of Prophylactic Human...